Teleste Oyj
Teleste Corporation Stock Exchange Release 22 March 2021 at 9.00 am (EET)
Teleste Corporation’s conveyance of own shares based on the long-term incentive plan 2018
A total of 8 225 Teleste Corporation's treasury shares were conveyed without consideration to the key employees participating in the plan period 2018-2020 of Teleste long-term share-based incentive programme 2018 in accordance with the terms and conditions of the plan. More detailed information about the launch of the plan period and its terms and conditions is available in a stock exchange release published on 8 February 2018.
The decision on the directed share issue is based on the authorisation granted to the Board of Directors by the Annual General Meeting of Shareholders held on 22 April 2020.
After the share delivery on 19 March 2021, the company holds a total of 768 194 own shares.
TELESTE CORPORATION
The Board of Directors
ADDITIONAL INFORMATION:
SVP HR Tuomas Vanne, phone +358 2 2605 611
DISTRIBUTION:
Nasdaq Helsinki
Main Media
www.teleste.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CNH Industrial N.V.9.11.2025 09:00:00 CET | Press release
CNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025
Ecorobotix SA8.11.2025 12:15:00 CET | Press release
Ecorobotix Showcases World-First AI Capability for Safe, Targeted Use of Non-Selective Contact Herbicides at Agritechnica
IOT Squared8.11.2025 11:00:00 CET | Press release
Saudi “Emerge” Emergency and Crisis Resilience Platform Named Among the World’s Best Smart City Solutions in the 2025 Smart City Awards
Novo Nordisk A/S8.11.2025 09:18:56 CET | Press release
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Teva Pharmaceutical Industries Ltd8.11.2025 00:00:00 CET | Press release
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
